Bexion Pharmaceuticals, founded in Covington, United States, is a biopharmaceutical company dedicated to developing innovative cancer therapies. The company's core mission is to change the narrative in oncology by leveraging their proprietary technology, Saposin C-dioleoylphosphatidylserine (SapC-DOPS), to treat a broad range of cancers. Their flagship product, BXQ-350, is designed to target and reduce sphingosine-1-phosphate (S1P) levels, offering a novel approach to cancer treatment. Bexion's market focus includes oncology and central nervous system (CNS) disorders, with ongoing clinical trials and a robust pipeline aimed at addressing unmet medical needs.

Notable individuals affiliated with Bexion Pharmaceuticals include its executive team and board of directors, who bring extensive experience in biopharmaceutical development and commercialization. The company has achieved key milestones in advancing BXQ-350 through various stages of clinical trials, demonstrating promising results in multiple cancer types. Bexion's impact is underscored by its commitment to pioneering breakthrough therapies that have the potential to significantly improve patient outcomes in oncology and CNS disorders.